of MDR-TB patients develop XDR-TB, which is even more difficult to treat. [2] In addition to emergence of MDR, diagnosis of TB still remains a challenge especially in cases of extrapulmonary TB, non-mycobacterial infections and a growing population of immunosuppressed individuals including people with HIV. The choice of these tests also varies in case of high-burden countries wherein the focus of diagnosis is on detection of active cases, whereas in low-burden countries, the focus is to diagnose latent infection. The diagnostic tests currently available in most public health systems in high-burden countries today largely rely on age old microscopy. What was good in 1882 remains to be good in 2017 too. It is only in the last few years that public health programmes are looking beyond conventional microscopy for diagnosis of new cases. In 2015, there has been a paradigm shift in the WHO from stop TB to end TB strategy. To achieve this, gaps in detection and treatment have to be bridged by rolling out newer and faster techniques in diagnosis as well as detection of MDR with the availability of these facilities at the peripheral centres. Computer software has not been used. Currently available diagnostics can be classified as those that: • Directly detect the actively growing bacilli • Indirectly detect the immune response against the bacilli.
Direct detection of infection includes microscopy, culture, antigen detection and nucleic acid detection whereas indirect methods of detection include detection of immune response by tuberculin skin testing (TST) and interferon-gamma release assays (IGRAs). Other newer and experimental methods include volatile organic compounds (VOCs) detection and detection of beta-lactamase. This is a thematic synthesis of data available on diagnosis in literature, preserving the conclusions of primary studies referred to and provided in the references. The review is restricted to descriptive themes derived from the primary studies and does not generate analytical themes.
dIrect detectIon Methods

Microscopy
Sputum smear microscopy still remains the basis for diagnosis of TB in developing countries. The most regular practice is acid-fast staining using carbol fuschin and fluorochrome dye-auramine/rhodamine. It is relatively fast, inexpensive and specific for TB in high incidence areas. Although highly specific, smear microscopy is insensitive -it detects roughly 50% of all the active cases of TB. [3] The higher load of bacilli (10,000 bacilli/ml) that need to be present leads to a varying sensitivity from 20% to 80% depending on various factors such as quality of the specimen and the training and motivation of laboratory personnel. [4] Sensitivity can be as low as 20% in children and HIV-infected people. [3] As per the current Revised National Tuberculosis Control Programme (RNTCP) guidelines, the patient should visit the clinic at least twice to submit a spot -early morning or spot-spot specimen. At least two ml specimen should be collected which should be mucopurulent. Sputum specimens should be examined within two days of collection. Studies have documented that the first sputum specimen detected 85.8% of TB cases with the second smear adding on to another 11.9%. [5] Relying on sputum microscopy alone may be dangerous from the public health point of view as 17% of smear-negative cases are known to transmit the disease. [6] Routine microscopy cannot differentiate between live and dead bacilli and hence cannot be used as a follow-up diagnostic test. It can neither be used to predict MDR nor the presence of non-tuberculous mycobacteria. Despite the multitude of disadvantages, in the absence of better alternatives, it is a useful tool in the basic laboratories common in developing countries. RNTCP has revised the diagnostic algorithm to allow for nucleic acid amplification detection based on cartridge based technologies (CBNAAT) for cases who are smear positive with presumptive MDR-TB/ or living in high MDR-TB areas (>5% and >20% among new and retreatment cases respectively). It also allows simultaneous testing of second specimen by the abovementioned cartridge based technology for smear negative cases with radiological abnormalities and even those solely based on high clinical suspicion in spite of negative CXR and smear.
Fluorescent microscopy with light-emitting diodes
Conventional fluorescence microscopy (FM) using the quartz-halogen lamps or high-pressure mercury vapour lamps was expensive, vulnerable and required expert handling. Light-emitting diodes (LEDs) are more robust, sustainable and user-friendly, thus allowing advantages of FM at peripheral health-care systems. Royal blue colour LED lamps used in these newer generation fluorescent microscopes have an extremely long life expectancy (10,000 h vs. 200 for a conventional mercury lamp). Furthermore, they do not produce ultraviolet (UV) light, do not require darkened rooms and significantly decrease the instrument's power consumption, allowing longer lasting battery life and thus decreasing the cost incurred, unlike older lamps. FM increases the sensitivity of smear microscopy as it allows a much larger area of the smear to be seen, resulting in more rapid examination of the specimen (up to four times faster), allowing sixty slides to be screened per day as opposed to 25 using the Ziehl-Neelsen (ZN) method. [7] Being WHO recommended in 2009, the RNTCP has adopted LED microscopy to replace ZN method in its designated microscopy centres (DMCs) across India.
Instability of fluorescent stains under field conditions and instability of the stained smears for blinded rechecking have been reported. [8] Proper training of laboratory personnel is imperative as detection and interpretation of results may be affected. [9] Unlike Ziehl Neelsen, international guidance on quality assurance for FM does not currently exist and is under development. [10] The sensitivity, specificity, cost-effectiveness and cost-benefit of this approach have not yet been adequately established.
Front-loaded microscopy
Microscopy services usually require the patients to make repeated visits to the healthcare facility leading to increased drop-out patient rates. The WHO definition (2009) of a smear-positive case allows patients to be diagnosed as TB on a single smear. In front-loaded microscopy, the first two specimens are collected and examined on the same day a patient present to the clinic. [11] Patients with negative smears are asked to return with a morning specimen the next day, depending on whether routine services are based on two or three specimens being examined. Thus, TB patients can be offered treatment on the first day they present.
Sodium hypochlorite (bleach) microscopy
The digestion of sputum with house-hold bleach before sputum smear preparation and microscopy has been reported to be an effective, simple method to improve the yield of smear microscopy even in high HIV prevalence settings. [3] Progress on the development of a bleach microscopy method has been complicated by the wide heterogeneity and lack of standardisation in methods described. A standardised bleach method, the Mathare sodium hypochlorite (MaSH) method, has recently been developed and evaluated in Medecins Sans Frontieres sponsored studies in Mathare, Nairobi. The addition of standardised sodium hypochlorite solution to sputum followed by overnight sedimentation resulted in a 15% increase in TB cases detected. [3] The MaSH method is now being evaluated by the WHO's Tropical Disease Research initiative under operational conditions in large multi-country studies.
Vital fluorescent staining
Monitoring the response to TB treatment is essential for early detection of treatment failure or drug resistance. The most common monitoring tool available in resource-limited settings is sputum smear microscopy using ZN or auramine staining. Smear positivity at 3 months or later should be investigated with a culture and drug susceptibility testing (DST), while smear positivity at 5 months or later defines treatment failure. As smear microscopy cannot distinguish viable from dead bacilli, it is possible that a significant proportion of patients on treatment may continue to cough up dead bacilli from necrotic lung cavities and would be falsely labelled as 'smear positive'. [12] Culture is the only test that can identify viable bacilli, but it requires several weeks to report results and needs a high level of expertise and laboratory infrastructure. Therefore, these patients are at an increased risk of receiving an unnecessary prolonged or new treatment regimen. Recent studies proposed a simple and instant method for TB treatment monitoring, based on a common fluorescent viability marker, fluorescein diacetate (FDA), [13] in combination with smear microscopy. Unlike most fluorescent stains, FDA stains only living, cultivable bacteria thus guiding antimicrobial therapy before culture reports come in.
Newer microscopic technologies
Automated microscopic technology by TBDx (Signature Mapping Medical Sciences, USA) integrates robotic loading of stained slides and automated high-resolution digital image analysis to provide a result in minutes. The system has a 200-slide capacity reducing the burden on technicians. Early studies suggested improved sensitivity over the human eye, but specificity was reduced; thus, manual review of positive slides was necessary. [14] Performance studies are underway in Nigeria and South Africa, with further studies planned for Asia.
A second innovation to assist a microscopist is CellScope, a portable digital FM that provides enlarged digitalised images for review. [15] Culture Culture still remains the gold standard for diagnosis of TB, and it also permits the diagnosis of drug resistance, including the emerging mutations. Traditional egg-based (Lowenstein-Jensen) and agar-based (Middlebrook 7H10/11) methods are widely used. The limit of detection is 100 bacilli/ml, thus increasing the sensitivity compared to smear, but the growth in a conventional egg-based medium takes anywhere from 4 to 8 weeks with an additional 4 weeks for drug sensitivity by the conventional proportion method. Thus, it takes a median of 70 days to diagnose a case of MDR-TB by conventional culture methods. [16] Other limitations include requirement of biosafety facilities that are expensive to build and maintain and specially trained laboratory technicians to perform the procedure. Hence, TB cultures are performed only at national reference laboratories or in-hospital laboratories in large cities. Few developing countries have the capacity for good-quality DST for the first-line drugs, and even fewer have the capacity to test for the second-line drug resistance. In most countries, TB culture is reserved for treatment failure and drug-resistant cases and specimens often need to be sent to distant laboratories leading to delay in processing of specimens which in turn effect results.
The most common detection method that is WHO endorsed in 2007, and adopted by the RNTCP, is a liquid culture using Middlebrook 7H9 broth -the mycobacterial growth indicator tube (MGIT), a non-radiometric detection method which measures the consumption of oxygen by fluorescence. [3] As bacteria grow in the culture, the oxygen is utilised causing it to be fluorescent when placed under UV light. Methods for testing for drug susceptibility follow the same principle but use two culture samples: one with a drug added and one without the drug (a growth control) and is called the modified 1% proportion sensitivity testing method (PST). Usually an economic variant of proportion sensitivity testing using Lowenstein Jensen medium is incorporated as a backup. While CBNAAT is the first line option for testing for drug resistance, wherever possible, especially in cases of rifampicin resistance, DST results of all the drugs should be made available. If the test drug is active against the TB bacteria, it will inhibit growth and suppress fluorescence. In the manual system, a technician visually identifies fluorescence using a hand-held UV lamp containing apparatus. Automated systems have the capacity for up to 960 cultures at a time.
Such systems have been thoroughly evaluated in clinical settings and approved for the use in industrialised countries for years. Liquid culture systems provide results significantly faster than solid culture techniques: On an average, diagnosis can be performed in 9 days for a smear-positive case to 16 days for a smear-negative case. [17] A negative result is issued by 42 days and DST takes an average 7-14 days (range 4-14 days) after the initial culture. [3] Automated systems can benefit laboratories with a high workload and provide standardised reading of samples. Such systems have a sensitivity and specificity of nearly 100% (and marginally less for manual systems). Studies have shown that both automated and manual systems perform well in the detection of INH and RIF susceptibility but are not as effective for ethambutol (EMB) and streptomycin. [18, 19] Liquid media are more prone to contamination than solid media, leading to invalid results unless carefully controlled. Automated machines must be maintained, requiring on-site technical support from manufacturers or their agents. Internal quality control of culture involves testing of each batch for sterility and quality strain H37Rv for growth parameters. For DST; a sensitive strain (H37Rv) and mono-resistant strains are tested batch wise. For obtaining accreditation for DST random 10/100 isolates tested in the laboratory are sent to the national reference centre (NRL) in the first stage for real time assessment of the laboratory. This is followed by second stage for actual test of performance; 30 isolates are sent from the NRL annually to the laboratory. Concordance of >90% is required for isoniazid and rifampicin. Besides the MGIT, other culture methods are enumerated in Table 1 .
Tools for rapidly identifying the species of culture isolates
Rapid speciation is necessary for the isolates grown in culture to differentiate between M. tuberculosis (MTB) complex and other species of Mycobacteria. Conventional biochemical methods of speciation using para-nitrobenzoic acid can take weeks. Strip speciation test can detect a TB-specific antigen (MPT 64) from positive liquid or solid cultures to confirm the presence of organisms belonging to M. tuberculosis complex. M. tuberculosis protein 64 (MPT-64) antigen is an M. tuberculosis complex (MTBC)-specific antigen secreted during bacterial growth. Studies have demonstrated that the rapid speciation tests compare favourably with other established phenotypic or genotypic methods. This test provides results within 15 min and is highly sensitive and specific. Sensitivity and specificity were found to be 98.6% and 97.9%, respectively, for the Capilia TB assay (Taunus, Japan), 99.0% and 100%, respectively, for the SD TB Ag MPT64 rapid test (Standard Diagnostics, South Korea) and 100% and 92.4% for the BD TBcID (Becton Dickinson, Sparks, MD). [25] [26] [27] Other than the equipment needed to culture TB, no additional equipment or consumables are needed to perform the test and it can detect M. tuberculosis complex even when mixed with non-tuberculous Mycobacteria. 
Antigen detection
Lipoarabinomannan (LAM) is a 17.5 kD glycolipid found in the outer cell wall of mycobacterial species. [28] LAM is one of the three major groups of interrelated lipopolysaccharides within the mycobacterial cell wall. All these molecules are non-covalently attached to the mycobacterial plasma membrane through the glycophospholipid anchor and extend to the surface of the cell wall. It is immunogenic and a major virulence factor promoting survival in human host. The test is available as an ELISA or dipstick method with a turnaround time (TAT) of 4-6 h or 20 min depending on the test kit used.
The WHO recommends that it should not be used for the diagnosis of TB, except for HIV-positive in-patients with signs and symptoms of TB (pulmonary and/or extrapulmonary) who have a CD4 cell count ≤100 cells/µL or HIV-positive patients who are seriously ill, regardless of the CD4 count. For TB diagnosis among symptomatic patients, overall lateral flow-LAM pooled sensitivity was 44% and pooled specificity was 92%. Several hypotheses may explain the higher sensitivity of urine LAM detection in patients with HIV-related immunosuppression, including higher bacillary burden and antigen load, greater likelihood of TB in the genitourinary tract and greater glomerular permeability that allows increased antigen levels in urine.
Molecular detection: Nucleic acid amplification tests
Most molecular methods that are WHO endorsed detect the nucleic acid (DNA) of both live and dead bacilli. [20] Measurement of CO 2 13.7 days Culture WHO endorsed not DST VersaTREK/ESP(automated) [21] Measurement of pressure 15.5 days Culture WHO endorsed not DST Micro-colony detection (MODS) [22] Liquid culture in microplates 9 days for culture, 7 days for MDR WHO endorsed 2009, requires inverted microscope TLA [23] Middlebrook agar 11-14 days Not WHO endorsed Nitrate reduction assay or colorimetric assay [24] Detects viable cells 10 [4] Since most of these tests involve amplification of target DNA, they are extremely susceptible to contamination from amplicons derived from positive specimens. Thus, strict infrastructure requirements must be observed, negative controls and inhibition controls must be included in each run to detect any potential amplicon contamination and inhibitors present, and wipe tests should be performed monthly to ensure that work areas remain clean. The advantage of these methods is that M. tuberculosis complex can be rapidly detected and identified; however, MTB cannot be ruled out due to issues related to sensitivity and inhibition. The pooled sensitivity and specificity of these tests were 85% (range, 36%-100%) and 97% (range, 54%-100%), respectively. [4] These techniques also have an important role in diagnosis of tuberculous meningitis. [4] Currently, three methods exist; the first two being WHO recommended: 1. Cartridge-based NAAT (CB-NAAT) 2. Line probe assay (LPA) 3. Loop-mediated amplification (LAMP).
Cartridge-based nucleic acid amplification test
The CB-NAAT is a semi-quantitative nested real-time PCR which detects both MTB and RIF resistance directly from clinical specimens. It is the WHO-recommended method in 2010 for the diagnosis of both pulmonary and extrapulmonary TB and for diagnosing paediatric TB. Under the current RNTCP guidelines, it is recommended for diagnosis of drug resistant-TB (DR-TB) in presumptive DR-TB and upfront diagnosis of TB in key population like paediatric tuberculosis, extra-pulmonary cases and people living with HIV. The analytical limit is 131 CFU/ml and the TAT is 2-3 h. Results can be ideally available while patient waits in the clinic. Because the cartridges are self-contained, the problem of cross-contamination between samples is eliminated. Sputum is liquefied and inactivated with a sample reagent which kills over 99.9% of TB bacilli in the specimen, and 2 ml of the material is transferred into a cartridge and this is inserted in the MTB-RIF test platform. Inside the cartridge, the sample is automatically filled, washed, filtered, by ultrasonic lysis of the filter captured organisms to release the DNA. It uses three specific primers and five unique molecular probes to ensure high degree of specificity. The primers amplify a portion of the rpoB gene 81 bp RIF resistance determining region. The probes are capable to differentiate between wild-type (WT) and conserved sequence and mutations in the core region.
The sensitivity was 99.8% for smear-and culture-positive cases and 90.2% for smear-negative, culture-positive cases. [29] Issue to be considered while using CB-NAAT is the presence of mono-resistance to INH which is not detected in this test. INH mono-resistance is documented to be 7%-11% in the first-line treatment failures and newly diagnosed and previously untreated patients, respectively. [30] Loss of therapeutic efficacy of this important anti-TB drug has considerable implications for treatment and control strategies. Both live and dead bacilli are picked up by the CB-NAAT thus making this test in the current format useless to assess post-therapy efficacy. Concerns exist regarding false-positive RIF resistance results; hence, samples found to be resistant must be confirmed by a second Xpert MTB/RIF test or an LPA and phenotypic culture testing. In case an indeterminate result is obtained on the first specimen, a repeat testing of a new specimen by CBNAAT is required, if the result of this is also indeterminate, testing by culture and DST or Line Probe assay is mandated. Each cartridge has its internal quality control viz sample processing control and Probe Check control. If Probe check control fails the test is stopped and an error is generated (>5% errors need to be investigated). The sample processing control must be positive when MTB is NOT detected but may be positive or negative is MTB is detected. The test requires a trained and computer-literate operator, a stable supply of electricity and air-conditioned settings. [31, 32] 
Line probe assay
This strip test detects TB DNA and genetic mutations associated with drug resistance from smear-positive sputum specimens or culture isolates after DNA extraction and PCR amplification. This is a hybridisation assay that allows differentiation between Mycobacterium species. Each strip consists of 27 reaction zones (bands), including six controls (conjugate, amplification, M. tuberculosis complex, rpoB, katG and inhA controls), eight rpoB WT and four mutants (MUT) probes, one katG WT and two MUT probes and two inhA WT and four MUT probes. Theoretically the TAT is 5-6 h but the entire procedure usually takes upto 72 hours. It has a good sensitivity and specificity when performed on smear-positive and on culture isolates. Sensitivity, specificity and positive and negative predictive values were 98.9%, 99.4%, 97.9% and 99.7% for the detection of RIF resistance; while it was 94.2%, 99.7%, 99.1% and 97.9%, respectively, for the detection of INH resistance and 98.8%, 100%, 100% and 99.7%, respectively, for the detection of MDR compared to conventional results, thus confirming their value in rapid screening of patients suspected of MDR-TB. [33] WHO has endorsed LPA for MDR-TB in 2009. Two commercially available products are (1) InnoLiPA assay-Innogenetics, Belgium, and (2) Hain Lifescience GenoType ® MTBDRplus.
Geographical variation in the prevalence of mutations associated with RIF and in particular with INH resistance may result in varying performance of LPAs in different epidemiological settings. Introduction of LPAs should preferably be preceded by an assessment of sensitivity and specificity of these assays in a representative collection of MDR and non-MDR isolates at country or at regional level.
LPAs are as complex to perform as conventional culture and DST and require skilled and well-trained laboratory personnel, as well as adequate laboratory space and design (BSL-2/3 level laboratory with Class II Biological Safety Cabinet) to reduce the risk of false-positive results. LPAs do not eliminate the need for conventional culture and DST capability as culture remains necessary for definitive diagnosis of TB in smear-negative patients while DST is required to confirm if not diagnose MDR/XDR TB.
Detection of resistance to the second-line drugs: At present, the 'gold standard' DST method measures phenotypic resistance by the culture-based indirect proportion method, which has been standardised for solid and liquid media for the detection of ofloxacin (OFX) and AMK resistance. [34, 35] Using these platforms, a DST may take anywhere between 10 days and 6 weeks. Excluding second-line drug resistance is a critical prerequisite for identifying patients who can be placed on the shorter MDR-TB regimen. Hain's MTBDRsl version was developed with this in mind to shorten the TAT of second-line DST testing to 1-2 days. These assays detect mutations in the gyrA gene (fluoroquinolone resistance), rrs gene (KM, AMK and CM resistance) and embB gene (EMB resistance). Any smear-positive or MDR culture-positive patient (adult or children) who has a positive Hain MDRplus assay may undergo the MTBDRsl version. This enables a rapid diagnosis of pre-XDR or XDR-TB in a smear-positive patient or if an MDR isolate is used. The sensitivity for detecting OFX, AMK and extensive drug resistance directly from clinical samples was 90.7%, 100% and 92.3%, respectively, and the specificity for detection was 98.1%, 99.4% and 99.6%, respectively. [36] Inclusion of moxifloxacin in an RIF-resistant or MDR-TB regimen is best guided by phenotypic testing. [2] This test is the first and only currently WHO-recommended rapid test in May 2016 for the detection of additional resistance in MDR-TB patients as well as XDR-TB. [2] Detection of second-line resistance by the second LPA means that MDR-TB patients should not be given the shorter treatment regimen as this leads to the development of XDR-TB and treatment failures. These recommendations do not eliminate the need for phenotypic DST to confirm resistance to other drugs and to monitor the emergence of additional drug resistance during treatment. The NRL retests 20/50 duplicate strains from a participating laboratory. This is followed by annual proficiency testing.
Internal and external concordance should be >95%. Both, CB-NAAT and LPA are WHO-recommended technologies adopted by the RNTCP at IRLs in India.
Loop-mediated amplification
Molecular amplification methods are proven technologies for the detection of TB but have not been widely used in remote settings because of the cost and complexity. LAMP is a simple, rapid, specific and cost-effective nucleic acid amplification method solely developed by Eiken Chemical Co., Ltd, Japan. [37] It is characterised by the use of four different primers specifically designed to recognise six distinct regions on the target gene and the reaction process proceeds at a constant temperature using auto-cycling strand displacement reaction targeting the six regions of the gyrB and 16S rRNA genes. Amplification and detection of gene can be completed in a single step, by incubating the mixture of samples, primers, DNA polymerase with strand displacement activity and substrates at a constant temperature (about 65°C). It provides high amplification efficiency, with DNA being amplified 109-1010 times in 15-60 min. Because of its high specificity, the presence of amplified product can indicate the presence of target gene. LAMP is a simple isothermal DNA amplification method that does not require a thermocycler or detection system and allows visual detection of amplification, possibly allowing it to be used at lower levels of the health system. It detects M. tuberculosis complex but does not detect resistance. The assay had a detection limit of 5-50 copies of purified DNA with a 60-min incubation time. The reaction time could be shortened to 35 min for the species identification of M. tuberculosis complex, Mycobacterium avium and Mycobacterium intracellulare from a solid medium culture. This LAMP-based assay is simple, rapid and sensitive; a result is available in 35 min for a solid medium culture and in 60 min for a liquid medium culture or for a sputum specimen that contains a corresponding amount of DNA available for testing.
Various other isothermal NAAT includes: [38] • Recombinase polymerase amplification (RRA, Twist Dx, UK) • Cross-priming amplification (CPA-China) • Helicase-dependent amplification (HAD-USA) • Nicking enzyme amplification reaction (NEAR-USA) • Epistem (UK) and Xceleris (India) are working on providing a rapid TB diagnostic test using gene drive technology. This is a hand-held device which incorporates a rapid nucleic acid amplification specific to M. tuberculosis complex as well as RIF resistance.
IndIrect Method of detectIon
The lack of a distinctive antibody response and inability to differentiate latent infection from active disease compromised immunoassay technologies to such an extent that in 2012, the WHO issued a negative endorsement, urging practitioners not to use serological tests for diagnosis of TB. [39] Exposure to MTB may result in latent TB infection. A person with latent TB infection usually leads a healthy life without developing active TB disease. Two billion people have latent TB infection, but only a fraction (<10 million a year) fall sick with active TB disease. [40] TST and IGRA cannot differentiate between latent TB and active TB.
Tuberculin skin testing
Popularly known as Mantoux test involves injecting the purified protein derivative (PPD) of MTB intradermally in the forearm and the resulting reaction is read after 48-72 h. [41] 
Interferon-gamma release assay
This is an in vitro assay wherein T-cells sensitised with MTB on encountering mycobacterial antigen (early secretory antigenic target 6 [ESAT-6] and culture filtrate protein 10 [CFP-10] and TB7.7), release interferon-gamma (a TH1 cytokine). [43] Advantages of this test are that the antigen used is recognised by T-cells of TB patients and not by BCG-vaccinated or healthy unvaccinated individuals. It has a very high specificity and much less likely than the TST to be confounded by exposure to environmental mycobacteria or by prior BCG vaccination. There are insufficient data and low-quality evidence on the performance of IGRAs in low-and middle-income countries, typically those with a high TB and/or HIV burden. In 2011, WHO has recommended against the use of IGRAs in these scenarios. IGRAs and the TST cannot accurately predict the risk of infected individuals developing active TB disease.
Neither IGRAs nor the TST should be used for the diagnosis of active TB disease. IGRAs are costlier and technically complex to do than the TST. Given comparable performance but increased cost, replacing TST by IGRAs as a public health intervention in resource-constrained settings, including India, is not recommended. [40] RNTCP advises against use of IGRAs for diagnosis in adults in high burden countries.
other IndIrect Methods
Volatile organic compounds
'In persons affected with phthisis, if the sputa which they cough up have a heavy smell when poured upon coals, and if the hairs of the head fall off, the case will prove fatal,' Hippocrates, Greek physician 460-410 BC. [44] These VOCs can be detected in urine, sputum and breath using a mass spectrophotometer and a gas chromatography.
Giant African pouched rats (Cricetomys gambianus) are trained to detect TB in sputum specimens by smell alone.
In the study conducted in Sub-Saharan African countries by rats trained to sniff out TB-positive or TB-negative sputum specimens. The sensitivity was found to be 73% and specificity 93%. [45, 46] A breath analyser test was developed as a point of care test by Menssana Inc. to be used in the community to screen high-risk groups. Patients cough into a disposable device which is placed in the instrument for detection of VOCs. The instrument is fully portable and runs off rechargeable AA batteries. The test is performed and readout obtained in under 10 min. Limited performance data are available and further evaluation studies are required. [47] 
Beta-lactamase detection
A promising alternative to smear microscopy is a detection of a metabolic signature of MTB. Recently, a panel of fluorogenic substrates metabolised by BlaC, a TB-specific β-lactamase, was developed. [48] A prototype under development by Global Biodiagnostics, Temple, TX, USA, demonstrated high specificity and sensitivity (10 CFU in unprocessed sputum) and enabled detection in a homemade box containing a LED, filters and a mobile phone camera.
conclusIon At DMCs, LED microscopy to detect MTB has been adopted by the RNTCP to replace conventional ZN staining. In IRLs, commercial automated liquid culture-MGIT is the current gold standard for detecting MDR-TB and XDR-TB, including in smear-negative cases. The LPA is suitable to detect MDR-TB only in smear-positive cases. Genotypic automated NAATs have considerable advantage in programme management and surveillance of MDR-TB. The WHO has worldwide banned the use of commercial sero-diagnostic tests (gazette notification, vide 433E, 7 th June 2012) and the RNTCP discourages the use of the indirect test IGRA in India for adults.
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